Core Insights - The article provides an update on the monthly moving averages for the S&P 500 and the Ivy Portfolio after the last business day of the month [1] Group 1: S&P 500 - Monthly moving averages for the S&P 500 are tracked to assess market trends and performance [1] Group 2: Ivy Portfolio - The Ivy Portfolio is based on the asset allocation strategy utilized by endowment funds from prestigious institutions such as Harvard and Yale [1]

Core Insights - The article provides an update on the monthly moving averages for the S&P 500 and the Ivy Portfolio after the last business day of the month [1] Group 1: S&P 500 - Monthly moving averages for the S&P 500 are tracked to assess market trends and performance [1] Group 2: Ivy Portfolio - The Ivy Portfolio is based on the asset allocation strategy utilized by endowment funds from prestigious institutions such as Harvard and Yale [1]

Core Insights - The article provides an update on the monthly moving averages for the S&P 500 and the Ivy Portfolio, which is based on the asset allocation strategy of prestigious endowment funds from Harvard and Yale [1] Group 1 - The S&P 500 moving averages are tracked to assess market trends and performance [1] - The Ivy Portfolio serves as a benchmark for investment strategies, reflecting the asset allocation used by elite endowment funds [1]

Core Insights - Progyny is a leader in fertility benefits, providing comprehensive, outcomes-based solutions that enhance treatment success and manage costs, distinguishing itself in a rapidly expanding healthcare niche [2] - The stock has significantly outperformed competitors with a 90% return over the last year, indicating strong market confidence in its future earnings potential [3] Revenue Growth - Progyny achieved an impressive revenue growth of 11.41% over the last twelve months (LTM), which is higher than most competitors, reflecting strong demand for its fertility benefits [2] - Despite this growth, GMED shows superior growth rates compared to Progyny [2] Profitability Metrics - Progyny's free cash flow margins stand at 15.25% LTM, showcasing competitive performance [2] - The operating margin for Progyny is 6.77% LTM, which is lower than larger competitors like Stryker (19.6%), indicating a less profitable service model compared to device sales [2] - The operating margin of Progyny is slightly higher at 6.8%, but still lags behind its peers [3] Valuation - Progyny's price-to-earnings (P/E) ratio is 40.78, which is considered moderate to high, suggesting limited upside potential if growth slows down [2] - The stock has realized a gain of 94.8%, indicating strong market expectations for its future performance [3]